Cathelicidin LL-37 for Health & Longevity - Quick Reference Sheet
evipedia.ai ← Back

Cathelicidin LL-37 for Health & Longevity

Created on 08/06/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

A natural defense peptide the body makes itself. It breaks open microbes and speeds wound closing in laboratory work; human testing is thin and points both ways. Those same properties turn the immune system against the body's own tissue, push cholesterol into arteries, and feed some tumors. Best characterized is the body's own production, governed by vitamin D and fiber. (Full Review)

Protocol

Topical protocol from the venous leg ulcer trial
0.5 mg/mL
Hydrogel applied twice weekly to a debrided ulcer bed for 4 weeks. The same concentration failed to beat placebo in the larger phase IIb trial in the same indication.
Endogenous induction through vitamin D
2,000–5,000 IU daily
Cholecalciferol titrated to a 25-hydroxyvitamin D of 40–50 ng/mL, taken with the largest fat-containing meal. The approach with the deepest safety record.
Endogenous induction through histone deacetylase inhibition
500 mg twice daily
Sodium phenylbutyrate with cholecalciferol 5,000 IU daily for 8 weeks. Dietary analogue: butyrate or tributyrin at 300–600 mg daily.
Time to effect
Topical wound healing
4 weeks
Separation from placebo in healing rate emerged over the 4-week treatment phase, with wound area reductions of 50–68% measured at its end.
Endogenous induction
8–12 weeks
25-hydroxyvitamin D takes 8–12 weeks to plateau on a fixed daily dose; the cathelicidin rise was measurable by day 5 after a single very large loading dose.
Local reactions
Hours to days
Serious cutaneous toxicity in the melanoma case report emerged at approximately 45 days.

Benefits

Contraindications
  • Moderate-to-severe plaque psoriasis (Psoriasis Area and Severity Index 10 or above, or 10% or more body surface area), and any psoriasis with active plaques
  • Papulopustular or erythematotelangiectatic rosacea of any severity
  • Systemic lupus erythematosus meeting 2019 classification criteria, psoriatic arthritis, or seropositive rheumatoid arthritis with anti-citrullinated protein antibodies
  • Active malignancy, or treated malignancy of the ovary, lung, breast, prostate, pancreas, or skin within 5 years of documented disease-free status
  • Established atherosclerotic cardiovascular disease (prior myocardial infarction or stroke, coronary artery calcium above 100 Agatston units, or lipoprotein(a) above 125 nmol/L)
  • Systemic mastocytosis, chronic spontaneous urticaria, or documented mast cell activation syndrome
  • Pregnancy and lactation
  • Men currently attempting conception
  • Severe congenital neutropenia, chronic granulomatous disease, or other primary immunodeficiency
Key Interactions
  • Systemic and topical corticosteroids (prednisone, dexamethasone, hydrocortisone, clobetasol propionate, fluticasone)
  • Systemic retinoids (isotretinoin, acitretin) and high-dose vitamin A
  • Heparin and heparin-like anticoagulants (unfractionated heparin, enoxaparin, dalteparin, fondaparinux, danaparoid)
  • Antibiotics acting on the bacterial envelope (aminoglycosides such as gentamicin, polymyxins such as colistin, glycopeptides such as vancomycin, beta-lactams such as amoxicillin)
  • Over-the-counter nonsteroidal anti-inflammatory drugs (ibuprofen, naproxen, aspirin)
  • Over-the-counter antihistamines (cetirizine, fexofenadine, diphenhydramine)
  • Vitamin D3 (cholecalciferol) and calcitriol
  • Butyrate, tributyrin, and sodium phenylbutyrate
  • Nicotinamide, curcumin, and sulforaphane
  • Omega-3 fatty acids (eicosapentaenoic acid and docosahexaenoic acid)

Risk & Side Effects

  • High: Local skin and injection-site reactions; loss of benefit and cytotoxicity at higher concentrations
  • Medium: Triggering or worsening of psoriasis; triggering or worsening of rosacea; mast cell degranulation and pseudo-allergic reactions
  • Low: Acceleration of atherosclerosis; tumor promotion in susceptible tissues; contribution to systemic autoimmunity; adverse effects on male reproductive function
  • Speculative: Systemic toxicity from injected or nebulized peptide; immunogenicity against the body's own peptide; harm from contaminants in unregulated product

Monitoring

Marker Target Why
25-hydroxyvitamin D 40–50 ng/mL Sets the substrate for cathelicidin gene induction and predicts who can respond
Serum calcium (albumin-corrected) 9.0–9.8 mg/dL Detects the one dose-limiting toxicity of the vitamin D induction route
Intact parathyroid hormone 15–35 pg/mL Confirms vitamin D sufficiency at the tissue level rather than the assay level
Plasma hCAP18/LL-37 500–800 ng/mL by research immunoassay The direct readout of the pathway being manipulated
High-sensitivity C-reactive protein Below 0.5 mg/L Flags whether the inflammatory system is already activated, which shifts the risk balance unfavorably
Apolipoprotein B Below 80 mg/dL Quantifies the particles the peptide drives into plaque macrophages
Lipoprotein(a) Below 75 nmol/L Identifies a genetically fixed atherosclerosis risk that compounds the peptide's lipid-handling effect
Complete blood count with differential Absolute neutrophil count 1.8–4.0 ×10⁹/L Neutrophils are the main reservoir of the precursor protein, so their number bounds endogenous supply
Antinuclear antibody Negative at 1:80 dilution Screens for the systemic autoimmunity in which LL-37 is a target antigen
Serum tryptase Below 8 ng/mL Identifies the expanded mast cell population that predicts severe flushing and wheal reactions

Cadence: Baseline panel before any use, then inflammatory and skin assessment at 4 weeks, the full panel repeated at 12 weeks, and thereafter every 6–12 months for anyone continuing an induction strategy indefinitely. Serum calcium is checked at 12 weeks whenever cholecalciferol above 2,000 IU daily is used.

Qualitative Assessment

  • Appearance of the application or injection site at 24, 48, and 72 hours, with attention to whether erythema is resolving or persisting
  • Any new verrucous, warty, blistering, or scaly lesion anywhere on the body
  • Facial flushing, burning, or stinging, which would indicate the rosacea mechanism becoming active
  • Itching, hives, or wheals appearing within minutes to hours of application
  • Rate of wound edge advance and granulation quality where a wound is the target, photographed under consistent lighting at weekly intervals
  • Frequency and duration of upper respiratory infections over a season
  • New joint pain, morning stiffness, or unexplained rash
  • Energy, sleep quality, and cognitive clarity
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.